| Literature DB >> 35099633 |
Lasse Slumstrup1,2, Susanne Eiholm3, Astrid Louise Bjørn Bennedsen4, Dea Natalie Munch Jepsen3,4, Ismail Gögenur4,5, Anne-Marie Kanstrup Fiehn3,4,5.
Abstract
Guidelines and requirements for diagnosing pathological complete response (pCR) in rectal adenocarcinoma following neoadjuvant treatment vary, and there is currently no consensus on the appropriate number of sections to examine per formalin-fixed, paraffin-embedded (FFPE) tissue block. The consequences of systematic use of deeper sections on the diagnostic accuracy and prognosis for patients classified as ypT0 rectal cancer were investigated. In this retrospective study, 23 out of 155 patients who underwent neoadjuvant therapy and surgical resection between 2015 and 2020 were diagnosed with ypT0 rectal cancer. Three additional deeper sections were cut from each FFPE block from the primary tumor site and reviewed for presence of residual tumor cells. Additional sections revealed residual viable tumor cells in seven patients (30.4%), reducing the rate of pCR in the cohort from 14.8 to 10.3%. Of the seven patients, three patients later had local recurrence or distant metastasis during the follow-up period, compared with one patient with no residual tumor cells in deeper sections (p = 0.07). A nonsignificant reduction in disease-free survival (p = 0.08) was observed in the patients with residual tumor. Systematic use of deeper sections in evaluation of tumor regression in rectal cancer reveals the presence of residual tumor cells in a subset of patients originally diagnosed with pCR based on a single section per FFPE block. Although the results are not statistically significant, it cannot be excluded that accurately distinguishing complete from near-complete response may be clinically relevant for prognostic prediction.Entities:
Keywords: Neoadjuvant treatment; Pathological complete response; Rectal cancer; Tumor regression
Mesh:
Year: 2022 PMID: 35099633 DOI: 10.1007/s00428-022-03287-7
Source DB: PubMed Journal: Virchows Arch ISSN: 0945-6317 Impact factor: 4.064